Figure 2

![Figure 2: Visual summary of the pathways and interactions relevant to topical Finasteride, as discussed in the context of the most prevalent kind of alopecia, androgenetic alopecia, commonly known as male or female pattern hair loss, affec.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561660/bin/cureus-0015-00000044949-i02.jpg)

> Source: Akshunna Keerti et al. "Topical Finasteride: A Comprehensive Review of Androgenetic Alopecia Management ." *Cureus*, 2023. PMID: [37818522](https://pubmed.ncbi.nlm.nih.gov/37818522/)

<figure>
  <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561660/bin/cureus-0015-00000044949-i02.jpg" alt="Visual summary of the pathways and interactions relevant to topical Finasteride, as discussed in the context of the most prevalent kind of alopecia, androgenetic alopecia, commonly known as male or female pattern hair loss, affec." />
  <figcaption>Figure 2. Visual summary of the pathways and interactions relevant to topical Finasteride, as discussed in the context of the most prevalent kind of alopecia, androgenetic alopecia, commonly known as male or female pattern hair loss, affec.<br>  Source: Akshunna Keerti et al. "Topical Finasteride: A Comprehensive Review of Androgenetic Alopecia Management ." <em>Cureus</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37818522/">37818522</a></figcaption>
</figure>